CCM
VRTX icon

Cinctive Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Cinctive Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-25,000
Closed -$10.2M – 513
2023
Q4 		$10.2M Buy
+25,000
New +$9.24M 0.68% 37

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Cinctive Capital Management's VRTX Position: Q1 2026 in Review

Cinctive Capital Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2026: 5,049 shares worth $2.25M. The stake represents 0.15% of the portfolio and ranks #196 among its holdings. This is a return to the name: Cinctive Capital Management previously reported a position in VRTX as recently as Q1 2025.

Cinctive Capital Management first reported a position in VRTX in Q4 2019 and has held it in 8 quarters since. The position peaked at $6.73M in Q1 2025. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Cinctive Capital Management held 5,049 shares of Vertex Pharmaceuticals worth $2.25M as of Q1 2026.
  • Vertex Pharmaceuticals was a new Cinctive Capital Management position in Q1 2026.
  • Vertex Pharmaceuticals made up 0.15% of Cinctive Capital Management's portfolio in Q1 2026, its #196 holding.
  • Cinctive Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 8 quarters since.
  • Cinctive Capital Management's Vertex Pharmaceuticals position peaked at $6.73M in Q1 2025.
  • 1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Cinctive Capital Management's 13F filing for Q1 2026, filed 15 May 2026.